Trametinib for Painful Glomus Tumors in a Patient with Neurofibromatosis Type 1

Can J Neurol Sci. 2023 May;50(3):477-478. doi: 10.1017/cjn.2022.36. Epub 2022 Mar 31.

Authors

Seth A Climans^#^{1

2}, Ronald C Ramos^#^{1

3}, Dimitri J Anastakis⁴, Warren P Mason¹

Affiliations

¹ Departments of Neurology and Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
² Department of Oncology, London Health Sciences Centre, London, Canada.
³ Division of Neurology, Hamilton Health Sciences, Hamilton, Canada.
⁴ Division of Plastic and Reconstructive Surgery, Department of Surgery, Toronto Western Hospital, Toronto, Canada.

^# Contributed equally.

PMID: 35357288
DOI: 10.1017/cjn.2022.36

No abstract available

Keywords: Glomangioma; Neuro-oncology; Neurofibromatosis type 1; Plastic surgery; Targeted chemotherapy.

Publication types

Letter

MeSH terms

Glomus Tumor* / complications
Glomus Tumor* / diagnostic imaging
Glomus Tumor* / pathology
Humans
Neurofibromatosis 1* / complications
Neurofibromatosis 1* / diagnostic imaging
Pain
Pyridones / therapeutic use
Pyrimidinones

Substances

trametinib
Pyridones
Pyrimidinones